<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Luccarelli J</submitter><funding>NIA NIH HHS</funding><funding>NIMH NIH HHS</funding><pagination>238-242</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8501161</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>37(4)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Right unilateral brief pulse (RUL-BP) electroconvulsive therapy (ECT) has been adopted as a technique for reducing the cognitive side effects of ECT relative to sine wave or bilateral treatments, but it is unknown how often patients are transitioned to alternative electrode placements. This study analyzes time in first lifetime acute course RUL-BP ECT.&lt;h4>Methods&lt;/h4>A single-center retrospective chart review was conducted of adult patients receiving a first lifetime course of ECT from 2000 to 2017 beginning with individualized seizure threshold determination using RUL-BP treatment parameters.&lt;h4>Results&lt;/h4>A total of 1383 patients met study criteria and received a mean number of 9.4 ± 3.1 treatments, of which 7.6 ± 3.3 were using RUL-BP stimuli. Only 37.5% of patients were transitioned from RUL to bilateral treatments. Younger patients and those diagnosed with bipolar disorder were more likely to transition from RUL-BP to bilateral treatments, but the overall number of treatments did not differ based on age or primary diagnosis.&lt;h4>Conclusions&lt;/h4>Among patients who begin treatment with RUL-BP ECT, more than 60% use exclusively those parameters throughout their acute course.</pubmed_abstract><journal>The journal of ECT</journal><pubmed_title>Duration of Treatment in Electroconvulsive Therapy Among Patients Beginning With Acute Course Right Unilateral Brief Pulse Stimuli.</pubmed_title><pmcid>PMC8501161</pmcid><funding_grant_id>R25 MH094612</funding_grant_id><funding_grant_id>R01 MH112737</funding_grant_id><funding_grant_id>R56 MH115187</funding_grant_id><funding_grant_id>R01 AG061100</funding_grant_id><funding_grant_id>R01 MH120991</funding_grant_id><pubmed_authors>Shannon AP</pubmed_authors><pubmed_authors>McCoy TH</pubmed_authors><pubmed_authors>Forester BP</pubmed_authors><pubmed_authors>Henry ME</pubmed_authors><pubmed_authors>Luccarelli J</pubmed_authors><pubmed_authors>Seiner SJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Duration of Treatment in Electroconvulsive Therapy Among Patients Beginning With Acute Course Right Unilateral Brief Pulse Stimuli.</name><description>&lt;h4>Objectives&lt;/h4>Right unilateral brief pulse (RUL-BP) electroconvulsive therapy (ECT) has been adopted as a technique for reducing the cognitive side effects of ECT relative to sine wave or bilateral treatments, but it is unknown how often patients are transitioned to alternative electrode placements. This study analyzes time in first lifetime acute course RUL-BP ECT.&lt;h4>Methods&lt;/h4>A single-center retrospective chart review was conducted of adult patients receiving a first lifetime course of ECT from 2000 to 2017 beginning with individualized seizure threshold determination using RUL-BP treatment parameters.&lt;h4>Results&lt;/h4>A total of 1383 patients met study criteria and received a mean number of 9.4 ± 3.1 treatments, of which 7.6 ± 3.3 were using RUL-BP stimuli. Only 37.5% of patients were transitioned from RUL to bilateral treatments. Younger patients and those diagnosed with bipolar disorder were more likely to transition from RUL-BP to bilateral treatments, but the overall number of treatments did not differ based on age or primary diagnosis.&lt;h4>Conclusions&lt;/h4>Among patients who begin treatment with RUL-BP ECT, more than 60% use exclusively those parameters throughout their acute course.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2025-04-25T20:53:07.838Z</modification><creation>2025-04-06T08:32:29.692Z</creation></dates><accession>S-EPMC8501161</accession><cross_references><pubmed>33840804</pubmed><doi>10.1097/yct.0000000000000768</doi><doi>10.1097/YCT.0000000000000768</doi></cross_references></HashMap>